Novo Commits $506M To Repurpose Irish Plant for Oral Wegovy Production
As Novo Nordisk continues to lose ground in the obesity market to rival Eli Lilly, the Danish company has started construction projects to establish the ex-Alkermes plant as a hub for supplying oral GLP-1 products to global markets.
Novo Commits $506M To Repurpose Irish Plant for Oral Wegovy Production Read More »
